Nihon rinsho. Japanese journal of clinical medicine
-
HER2 gene is overexpressed or amplified in approximately 30% of breast cancer. Breast cancer patients with HER2-overexpression or amplification have shortened disease free and overall survival. ⋯ However, much controversy exists on the optimal use of trastuzumab. In this paper, positioning of trastuzumab in the treatment algorithm for HER2 positive MBC as well as early breast cancer will be reviewed and discussed on the basis of our experience.